Gain Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
Independent Registered Public Accounting Firm Fees
Our independent public accounting firm is Ernst & Young AG, Lugano, Switzerland (PCAOB Auditor ID: 1460). The following is a summary and description of fees for the fiscal years ended December 31, 2025 and 2024 billed to us by Ernst & Young AG. All services and fees described below were pre-approved by the Audit Committee.
| · · · · · · | |||||
|---|---|---|---|---|---|
| · · Fiscal Year Ended | |||||
| · · 2025 · · 2024 | |||||
| Audit Fees(1) | | $638,201 | | $606,012 | |
| Tax Fees(2) | | | — | | 8,144 |
| Total Fees | | $638,201 | | $614,156 | |
| (1) | “Audit Fees” represent the aggregate fees and expenses for professional services rendered in relation to the audit of our consolidated financial statements on Form 10-K and the review of our quarterly condensed consolidated financial statements on Form 10-Q, and the statutory audit fees of our Swiss subsidiary. It also includes professional services rendered in connection with issuance of consents included in registration statements and issuance of comfort letters. |
| (2) | “Tax Fees” consist of fees and expenses for professional services mainly related to tax compliance and tax advice. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.